Public Market Listing
Live quotes, historical charts, and market capitalization for Asieris Pharmaceuticals are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
NepicastatNo recent activity | Phase 1 | DBHSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (12)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $10M | — | $91M | $16M | report ↗ |
View 11 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $30M | $24M | $129M | $36M | report ↗ |
| 2025-H1 | $18M | $16M | $100M | $22M | report ↗ |
| 2024-Q3 | $19M | $18M | $68M | $38M | report ↗ |
| 2024-H1 | $11M | — | $161M | $27M | report ↗ |
| 2024-Q1 | $3.4M | $9.5M | $291M | $12M | report ↗ |
| 2023-Q3 | $0.4M | $34M | $226M | $37M | report ↗ |
| 2023-H1 | <$0.1M | $26M | $187M | $27M | report ↗ |
| 2023-Q1 | $0 | $8.3M | $221M | $9.2M | report ↗ |
| 2022-Q3 | $0 | $25M | $101M | $24M | report ↗ |
| 2022-H1 | $0 | $14M | $113M | $14M | report ↗ |
| 2022-Q1 | $0 | $6.5M | $90M | $7.5M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $41M | — | $250M | — | report ↗ |
Asieris Pharmaceuticals reported 2025 revenue of $41M, up 46.2% YoY; the company’s own report cited operating revenue of RMB 277 million, up 37.49% YoY. Cash and equivalents were $250M (approximately RMB 1.692 billion), with R&D spend, net income, and quarterly burn not disclosed.
During 2025, the company advanced its Commercialization 2.0 strategy, and in March 2026 CEVIRA (APL-1702), the world’s first non-invasive treatment for precancerous cervical lesions, was approved in China. The EU marketing authorization application for CEVIRA is under review, and U.S. Phase III trial discussions are ongoing. Pipeline progress included APL-2302 Phase I/IIa clearance, APL-2401 regulatory approvals in China and Australia, APL-2501 IND plans for mid-2026, positive APL-1401 Phase Ib signals, and APL-1202 IND approval. The SYSTEM BLUE blue-light cystoscopy system also received market approval to work with Hexvix. No numeric guidance was provided, though management said 2026 is expected to mark an inflection point.